Teva Pharmaceutical Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $19.74 billion. The enterprise value is $35.11 billion.

Market Cap	19.74B
Enterprise Value	35.11B

Important Dates

The last earnings date was Wednesday, July 30, 2025, before market open.

Earnings Date	Jul 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.25% in one year.

Current Share Class	n/a
Shares Outstanding	1.15B
Shares Change (YoY)	+1.25%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	77.15%
Float	1.14B

Valuation Ratios

PE Ratio	n/a
Forward PE	6.37
PS Ratio	1.14
Forward PS	2.20
PB Ratio	2.79
P/TBV Ratio	n/a
P/FCF Ratio	22.17
P/OCF Ratio	14.19
PEG Ratio	0.91

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.76, with an EV/FCF ratio of 39.45.

EV / Earnings	n/a
EV / Sales	2.11
EV / EBITDA	7.76
EV / EBIT	10.03
EV / FCF	39.45

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 2.57.

Current Ratio	1.06
Quick Ratio	0.48
Debt / Equity	2.57
Debt / EBITDA	3.76
Debt / FCF	19.71
Interest Coverage	3.59

Financial Efficiency

Return on equity (ROE) is -2.42% and return on invested capital (ROIC) is 8.77%.

Return on Equity (ROE)	-2.42%
Return on Assets (ROA)	5.37%
Return on Invested Capital (ROIC)	8.77%
Return on Capital Employed (ROCE)	12.38%
Revenue Per Employee	$451,480
Profits Per Employee	-$4,263
Employee Count	36,830
Asset Turnover	0.41
Inventory Turnover	2.26

Taxes

In the past 12 months, Teva Pharmaceutical has paid $94.00 million in taxes.

Income Tax	94.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.76% in the last 52 weeks. The beta is 0.62, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+0.76%
50-Day Moving Average	16.69
200-Day Moving Average	17.21
Relative Strength Index (RSI)	62.17
Average Volume (20 Days)	12,483,401

Short Selling Information

Short Interest	49.89M
Short Previous Month	39.87M
Short % of Shares Out	4.37%
Short % of Float	n/a
Short Ratio (days to cover)	4.27

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $16.63 billion and -$157.00 million in losses. Loss per share was -$0.14.

Revenue	16.63B
Gross Profit	8.25B
Operating Income	3.50B
Pretax Income	131.00M
Net Income	-157.00M
EBITDA	4.52B
EBIT	3.50B
Loss Per Share	-$0.14

Full Income Statement

Balance Sheet

The company has $2.16 billion in cash and $17.54 billion in debt, giving a net cash position of -$15.38 billion or -$13.41 per share.

Cash & Cash Equivalents	2.16B
Total Debt	17.54B
Net Cash	-15.38B
Net Cash Per Share	-$13.41
Equity (Book Value)	6.83B
Book Value Per Share	5.95
Working Capital	759.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.39 billion and capital expenditures -$500.00 million, giving a free cash flow of $890.00 million.

Operating Cash Flow	1.39B
Capital Expenditures	-500.00M
Free Cash Flow	890.00M
FCF Per Share	$0.78

Full Cash Flow Statement

Margins

Gross margin is 49.60%, with operating and profit margins of 21.05% and -0.94%.

Gross Margin	49.60%
Operating Margin	21.05%
Pretax Margin	-0.41%
Profit Margin	-0.94%
EBITDA Margin	27.20%
EBIT Margin	21.05%
FCF Margin	5.35%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.25%
Shareholder Yield	-1.25%
Earnings Yield	-0.80%
FCF Yield	4.51%

Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $24.71, which is 43.58% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.71
Price Target Difference	43.58%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date	Jul 1, 2004
Split Type	Forward
Split Ratio	2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.57 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.57
Piotroski F-Score	6